Physician profile
William Oliver Mann
NPI 1649211715
$6,321.62
in general payments reported to CMS, 2019-2025
17 companies · $838 in 2025
The $838 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $789 · 2022: $1,699 · 2023: $1,784 · 2024: $1,211 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,695 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,694.62 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,750.72 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,164.92 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $753.06 | 2021-2025 | Caplyta |
| Alkermes, INC. | $687.25 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $633.97 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $402.83 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $168.33 | 2022-2025 | Ingrezza |
| Indivior INC. | $149.72 | 2021-2023 | Perseris, Sublocade |
| E.R. Squibb & Sons, L.L.C. | $126.44 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $105.31 | 2021-2022 | |
| Corium, LLC | $103.67 | 2022-2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $98.82 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $55.35 | 2021-2024 | Rexulti |
| Luye Pharma (USA) LTD. | $42.69 | 2025 | Erzofri Extended-Release |
| Ironshore Pharmaceuticals INC. | $36.83 | 2023 | Jornay Pm |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $24.69 | 2025 | Xelstrym |
| Almatica Pharma LLC | $17.02 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.